← Leaderboards
Jun He
Thomas Jefferson University
$3,802,681
Attributed
$4,125,086
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,125,086 · 5
By mechanism
R01$3,181,914 · 3
R00$747,000 · 1
K99$196,172 · 1
Top collaborators
- Ling-Zhi Liu1 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Philip N Tsichlis$14,961,127
- Steven B McMahon$11,125,471
- Renato V. Iozzo$16,721,043
- Eric Wickstrom$2,403,438
Others in their field
Other Emerging Leaders on “Overexpression”
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$9,634,868
- Robert Nicol · Broad Institute, Inc.$7,498,771
- Michael R Tadross · Duke University$6,418,169
- Terry Roemer · Prokaryotics, Inc.$5,773,697
- Yi Ye · New York University$5,437,303
- Montserrat C Anguera · University Of Pennsylvania$5,285,297
Research focus
OverexpressionAffectSignal PathwayCancer CellFutureTumorMolecularUp-RegulationPathway InteractionsMediatingNew Therapeutic TargetCancer TherapyCellsMalignant NeoplasmsResistanceMemberMalignant Breast NeoplasmCell LineFamilyAnimal ModelAngiogenesisIn VivoKnock-DownSignal Transduction
Grant awards (12)
MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response$644,810
R01 · FY2025 · CA · contact PI
MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response$264,296
R01 · FY2024 · CA · contact PI
MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response$631,914
R01 · FY2023 · CA · contact PI
MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response$644,810
R01 · FY2022 · CA · contact PI
Chromium in carcinogenesis and angiogenesis$337,440
R01 · FY2022 · ES · contact PI
New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer$249,000
R00 · FY2022 · CA · contact PI
Chromium in carcinogenesis and angiogenesis$337,440
R01 · FY2021 · ES · contact PI
New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer$249,000
R00 · FY2021 · CA · contact PI
NOX4 Mediates Oxidative Stress in Ovarian Tumor growth and treatment Response$321,204
R01 · FY2020 · CA · contact PI
New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer$249,000
R00 · FY2020 · CA · contact PI
New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer$98,086
K99 · FY2019 · CA · contact PI
New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer$98,086
K99 · FY2018 · CA · contact PI